Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit Kansagra, Shahrukh K. Hashmi, Michael Hudecek et al.|Bone Marrow Transplantation|2019Cited by 119
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular TherapyAnkit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Biology of Blood and Marrow Transplantation|2018Cited by 106
IL-4 drives exhaustion of CD8+ CART cellsCarli M. Stewart, Saad S. Kenderian|Nature Communications|2024Cited by 31
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemiaPaul J. Hampel, Philip A. Thompson, Mahesh Swaminathan et al.|Blood Advances|2024Cited by 19
ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S. Davids, Javier Pinilla Ibarz, Saad S. Kenderian et al.|Blood|2022Cited by 12